Chronic Constipation and Wegovy Use

Introduction to Wegovy Contraindications

The American College of Cardiology and other guideline societies recommend that patients with a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2 (MEN2), or history of severe hypersensitivity reaction to semaglutide should not use Wegovy 2
The decision to use Wegovy in patients with chronic constipation depends on the severity of baseline constipation and the patient's overall clinical picture, with severe gastroparesis or clinically meaningful gastric motility disorders representing relative contraindications 1, 2

Patients with mild-to-moderate functional constipation that is well-controlled with current management can generally proceed with Wegovy use 1
A slow titration schedule (0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, with 4 weeks at each dose) minimizes gastrointestinal side effects, which are dose-dependent 1, 2
Optimizing baseline constipation management before initiating Wegovy, ensuring adequate fluid intake, and considering prophylactic stool softeners or osmotic laxatives can help mitigate constipation risks 1, 2

Wegovy provides a mean weight loss of 14.9% at 68 weeks, with 64.9% of patients achieving ≥10% weight loss, and reduces cardiovascular death, nonfatal MI, or stroke by 20% (HR 0.80) in patients with established cardiovascular disease 1, 3
Gastrointestinal effects are typically mild-to-moderate, transient, and decrease over time, but can be severe in some cases 1, 2

If constipation proves prohibitive, alternative treatments such as tirzepatide, liraglutide 3.0 mg daily, or metabolic surgery may be considered 1